News
Investing.com -- Dyne Therapeutics, Inc. (NASDAQ: DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its ...
The UK’s new industrial strategy signals a decisive shift toward state-backed innovation, investment, and regulatory reform.
On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results